Main Article Content


Mother-to-child transmission (MTCT) accounts for the majority of new human immunodeficiency virus (HIV) infections among children worldwide. Post-natal prophylaxis along with other preventive measures have been very successful reducing transmission to babies born to mothers living with HIV infection to < 2%. Single-drug prophylaxis with Zidovudine (ZDV) is the mainstay regimen for infants in low-risk transmission settings. The optimal regimen for newborns of women with anti-retroviral (ARV)-resistant HIV is unknown. We present a baby born to a young mother living with highly resistant perinatally-acquired HIV and we discuss the challenges with giving postnatal ARV prophylaxis to her baby given the lack of dosing and safety data for many antiretroviral agents for neonates.  The baby received a combination of lamivudine and raltegravir for total of 6 weeks and he was not breast fed. He had negative HIV proviral DNA PCR at 6 weeks and 3 months and a negative HIV serology at 18 months of age.

Keywords: HIV, postnatal prophylaxis, neonate, antiretroviral, resistant.

Article Details

How to Cite
Al Yazidi, L. S., Britton, P. N., Gilroy, N., Lai, T., & Kesson, A. (2022). Post-Natal Anti-Retroviral Prophylaxis for Neonates Born to Mothers Living with Resistant Human Immunodeficiency Virus (HIV) Infection. Sultan Qaboos University Medical Journal, 1(1).